LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.38 2.22

Overview

Share price change

24h

Current

Min

1.3599999999999999

Max

1.42

Key metrics

By Trading Economics

Income

-2.4M

-40M

Sales

6.2M

45M

Profit margin

-90.427

Employees

485

EBITDA

-6M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+75% upside

Dividends

By Dow Jones

Next Earnings

7 May 2026

Market Stats

By TradingEconomics

Market Cap

-136M

420M

Previous open

-0.84

Previous close

1.38

News Sentiment

By Acuity

50%

50%

156 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Mar 2026, 22:42 UTC

Earnings

Prudential PLC 2025 Adjusted Operating Profit Rises

17 Mar 2026, 21:40 UTC

Earnings

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 Mar 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 Mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 Mar 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Mar 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 Mar 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 Mar 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 Mar 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 Mar 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 Mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 Mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 Mar 2026, 22:07 UTC

Earnings

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 Mar 2026, 22:05 UTC

Earnings

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 Mar 2026, 22:04 UTC

Earnings

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 Mar 2026, 22:03 UTC

Earnings

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 Mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 Mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 Mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 Mar 2026, 21:26 UTC

Earnings

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 Mar 2026, 21:09 UTC

Earnings

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 Mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 Mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 Mar 2026, 21:07 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 Mar 2026, 21:06 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 Mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 Mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 Mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 Mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Net $757.2M >ATD.T

17 Mar 2026, 20:50 UTC

Market Talk
Major News Events

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

75% upside

12 Months Forecast

Average 2.38 USD  75%

High 3 USD

Low 1.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

156 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat